Vietnam Generic Drugs Market, By Type (Small Molecule Generics, Biosimilars), By Mode of Drug Delivery (Oral, Parenteral, Topical, Others), By Form (Tablets, Capsules, Injections, Others), By Source (Contract Manufacturing Organizations, In-house), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others), By Application (Neurology, Oncology, Cardiovascular Diseases, Diabetes, Anti-Inflammatory Diseases, Others), By Region, Competition, Forecast & Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 2.67 Billion
CAGR (2026-2031)	6.88%
Fastest Growing Segment	Small Molecule Generics
Largest Market	Southern Vietnam
Market Size (2031)	USD 3.98 Billion

Market Overview

The Vietnam Generic Drugs Market will grow from USD 2.67 Billion in 2025 to USD 3.98 Billion by 2031 at a 6.88% CAGR. Generic drugs are pharmaceutical products bioequivalent to innovator drugs, containing the same active ingredients, dosage form, strength, and intended use, becoming available after patent expiry to offer cost-effective treatment alternatives. The Vietnam Generic Drugs Market is experiencing significant expansion, primarily driven by the rising prevalence of chronic diseases and increasing demand for affordable healthcare solutions among an aging population. Government initiatives and supportive policies, including universal health insurance coverage and incentives for local manufacturing, further stimulate market growth. According to the Ministry of Health's National Pharmaceutical Industry Development Strategy, in 2024, domestically produced medicines constituted approximately 49% of the total pharmaceutical value consumed in the country, reflecting a concerted effort to boost local production, much of which is generic.

However, the market faces a notable challenge from a complex and often lengthy regulatory approval process, which can delay market entry for new generic products and impose administrative burdens on manufacturers. Additionally, the reliance on imported raw materials for pharmaceutical production also poses an impediment to complete self-sufficiency and supply chain resilience.

Key Market Drivers

Rising NCD Burden Drives Demand for Affordable Generics
The rising burden of chronic and non-communicable diseases (NCDs) significantly drives the Vietnam Generic Drugs Market, necessitating affordable and accessible long-term treatment solutions. As the population ages and lifestyles evolve, conditions such as cardiovascular diseases, diabetes, and chronic respiratory illnesses are becoming more prevalent, requiring sustained medication management. This demographic shift places considerable pressure on healthcare systems and individual finances, increasing the demand for cost-effective generic alternatives. According to the World Health Organization, October 2025, in 'Health in every community: caring for people with noncommunicable diseases in Viet Nam', NCDs are responsible for 80% of deaths in Vietnam. This high mortality rate underscores the widespread impact of these conditions, making the availability of economical generic drugs crucial for public health and economic stability.

Policy Incentives and Public Investment Bolster Domestic Generics
Supportive government policies and regulatory frameworks further propel the generic drugs market by actively encouraging domestic pharmaceutical production and enhancing market accessibility. The Vietnamese government has implemented strategic incentives to foster local manufacturing, recognizing its role in reducing reliance on imports and ensuring drug security. For instance, according to LNT & Partners, December 2024, in 'KEY UPDATES IN THE AMENDED PHARMACEUTICAL LAW OF 2024', new investment incentives apply to pharmaceutical manufacturing projects with a total investment of 3,000 billion VND or more, provided they disburse at least 1,000 billion VND within three years. These policies aim to streamline approvals, attract investment, and ensure that domestically produced generics can meet the growing healthcare demands. Reflecting the substantial investment in public health, according to Viet Nam Social Security News, in 2024, the Health Insurance Fund disbursed VND142.9 trillion (US$5.63 billion) for the examination and treatment of more than 186 million health insurance participants. This extensive healthcare expenditure highlights the broad consumer base benefiting from affordable generic medications.

Download Free Sample Report

Key Market Challenges

Regulatory Complexity Impedes Market Entry
The Vietnam Generic Drugs Market faces a significant challenge from its complex and often lengthy regulatory approval process. This procedural intricacy directly impedes market expansion by delaying the entry of new generic products, thereby limiting patient access to affordable healthcare solutions. The extensive documentation requirements and administrative burdens associated with navigating the regulatory landscape contribute to prolonged timelines for market authorization.

Extended Approval Timelines Limit Investment and Viability
Such protracted review periods for new generic products diminish the commercial viability for manufacturers, hindering their ability to capitalize on patent expiries and respond efficiently to market demands. According to Global Advisory Experts' professional analysis of the regulatory framework, in 2025, the estimated timeline for obtaining marketing authorization for generic drugs typically spans 12 to 18 months from the submission of a complete application. This extended timeframe ultimately constrains market competition and can discourage investment in the local production and distribution of generic pharmaceuticals.

Key Market Trends

Vertical integration and domestic API production to strengthen Vietnam's generics
A significant trend in the Vietnam Generic Drugs Market is the increasing vertical integration within domestic generic drug manufacturing. This involves local pharmaceutical companies investing in upgrading their production capabilities and moving towards higher-value activities, including the domestic production of active pharmaceutical ingredients and advanced finished drug formulations. This strategic shift aims to enhance self-sufficiency, improve supply chain resilience, and boost the quality and competitiveness of locally produced generics. For instance, Imexpharm Corporation is proactively expanding its production capacity with plans to develop the Cat Khanh Pharmaceutical Complex, investing approximately VND1,495 billion ($59.8 million) in the third quarter of 2025. Such investments reduce reliance on imported raw materials and strengthen the domestic pharmaceutical value chain.

Biosimilars expansion drives affordable, high-value therapies
Another pivotal trend shaping the market is the growing adoption and development of biosimilars. These advanced generic versions of biologic drugs offer cost-effective treatment alternatives for complex and often chronic diseases. The focus on biosimilars represents a strategic move to address the rising demand for affordable high-value therapies and expand patient access. Companies are increasingly investing in the research, development, and market introduction of these complex products. Notably, STADA's Specialty segment, encompassing biosimilars, exceeded €1 billion in revenues in 2025, demonstrating 17% growth, indicating the expanding significance of such high-value products. This trend diversifies Vietnam's generic drug portfolio, pushing innovation and fostering competition in specialized therapeutics.

Segmental Insights

Rapid Growth of Small Molecule Generics Driven by Chronic Disease Burden and Government Support
The Vietnam Generic Drugs Market is experiencing significant expansion, with Small Molecule Generics identified as the fastest-growing segment. This rapid ascent is primarily attributed to the increasing prevalence of chronic diseases, such as diabetes and cardiovascular conditions, which necessitate long-term, affordable treatment solutions for the populace. Small molecule generics offer considerably more cost-effective alternatives to branded pharmaceuticals, thereby improving accessibility for a wider demographic across diverse income levels. Moreover, supportive government initiatives, particularly from the Ministry of Health, actively encourage the adoption of generic drugs to manage healthcare costs and enhance patient access to essential medicines, further solidifying the segment's growth trajectory.

Regional Insights

Southern Vietnam: Core market driven by urbanization, healthcare infrastructure, and rising demand for generics.
Southern Vietnam stands as the primary region within the Vietnam Generic Drugs Market, driven by its robust economic development and significant urbanization, particularly centered around Ho Chi Minh City. This area functions as a pivotal commercial and healthcare hub, fostering a highly developed healthcare infrastructure that includes numerous hospitals, clinics, and extensive pharmaceutical distribution networks. The region benefits from a substantial presence of both domestic and international pharmaceutical companies, which utilize the well-established infrastructure for efficient product distribution. Moreover, elevated disposable incomes and an expanding, aging population facing a rising prevalence of chronic diseases collectively fuel a consistent demand for accessible and affordable generic medications across Southern Vietnam. The national regulatory framework, governed by the Drug Administration of Vietnam under the Ministry of Health, ensures market compliance.

Recent Developments

• In November 2025, Hanmi Pharmaceutical entered into an exclusive supply and license agreement with Viet-Phap, a prominent local pharmaceutical company in Vietnam. This collaboration aims to introduce several of Hanmi Pharmaceutical's antihypertensive combination drugs to the Vietnamese market. Under the agreement, Hanmi Pharmaceutical will provide the finished drug products, while Viet-Phap will be responsible for obtaining regulatory approvals, distribution, and sales within Vietnam. This partnership is set to enhance access to advanced hypertension treatments for approximately 15 million patients in Vietnam's steadily growing antihypertensive market, fostering local access to effective generic medications.
• In April 2024, TRAPHACO JOINT STOCK COMPANY announced its strategic focus on bolstering research and development capabilities to introduce new technology products. The company also declared its intention to launch its initial generic drugs into the Vietnamese market. To support these objectives, TRAPHACO is actively recruiting external R&D experts and increasing investments in its workforce and internal departments. This initiative aligns with the growing demand for cost-effective pharmaceutical solutions and contributes to the expansion of the Vietnam Generic Drugs Market by providing more accessible treatment options.
• In the final days of 2025, Imexpharm Corporation made a significant advancement in Vietnam's pharmaceutical sector by introducing its first "first generic" antibiotic. This next-generation product was manufactured in compliance with stringent EU-GMP standards. This development represents a pivotal shift, as it marks the first time generic antibiotics meeting such high international benchmarks have been produced domestically in Vietnam. The introduction of this product expands treatment options, offering lower costs while maintaining robust standards of efficacy and safety for patients within the Vietnam Generic Drugs Market.
• In the first eight months of 2025, a significant corporate collaboration occurred in the Vietnamese pharmaceutical industry. Livzon, an international entity, acquired a 65% stake in Imexpharm, a leading generic pharmaceutical company in Vietnam. This transaction involved an investment of approximately $221 million. This acquisition not only enhances Imexpharm's pharmaceutical manufacturing capabilities, particularly its EU-GMP certified facilities, but also positions Vietnam as a more prominent regional hub for pharmaceutical production. Such strategic investments drive growth and competitiveness within the Vietnam Generic Drugs Market.

Key Market Players

• Julphar
• Neopharma
• Gulf Pharmaceutical Industries
• Hikma Pharmaceuticals
• Pfizer
• Novartis
• Sanofi
• GSK
• Merck
• AstraZeneca

By Type	By Mode of Drug Delivery	By Form	By Source	By Distribution Channel	By Application	By Region
Small Molecule Generics Biosimilars	Oral Parenteral Topical Others	Tablets Capsules Injections Others	Contract Manufacturing Organizations In-house	Retail Pharmacies Hospital Pharmacies Online Pharmacies Others	Neurology Oncology Cardiovascular Diseases Diabetes Anti-Inflammatory Diseases Others	Northern Central Southern

Report Scope:

In this report, the Vietnam Generic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Vietnam Generic Drugs Market, By Type:

• Small Molecule Generics
• Biosimilars

• Vietnam Generic Drugs Market, By Mode of Drug Delivery:

• Oral
• Parenteral
• Topical
• Others

• Vietnam Generic Drugs Market, By Form:

• Tablets
• Capsules
• Injections
• Others

• Vietnam Generic Drugs Market, By Source:

• Contract Manufacturing Organizations
• In-house

• Vietnam Generic Drugs Market, By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Others

• Vietnam Generic Drugs Market, By Application:

• Neurology
• Oncology
• Cardiovascular Diseases
• Diabetes
• Anti-Inflammatory Diseases
• Others

• Vietnam Generic Drugs Market, By Region:

• Northern
• Central
• Southern